Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
Author:
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference36 articles.
1. Contribution of impaired mobility to patient burden in multiple sclerosis;MH Sutliff;Curr Med Res Opin,2010
2. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners;NG Larocca;Patient,2011
3. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis;AD Goodman;Ann Neurol,2010
4. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial;AD Goodman;Lancet,2009
5. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis;C Polman;N Engl J Med,2006
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study;Neurotherapeutics;2024-07
2. Drug Delivery to the Brain: Recent Advances and Unmet Challenges;Pharmaceutics;2023-11-23
3. Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier;Frontiers in Drug Delivery;2023-07-10
4. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-04
5. Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?;Pharmaceutics;2022-11-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3